Related Experiment Video
Updated: May 6, 2026

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Influenza A/H1N1 in pediatric oncology patients
Amit Dotan1, Shalom Ben-Shimol, Yariv Fruchtman
1*Pediatric Hemato-Oncology Unit †Pediatric Infectious Diseases Unit ‡Viral Clinical Laboratory, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Insights
Pandemic influenza A/H1N1 in immunocompromised children with cancer showed similar clinical features regardless of infection status. Early antiviral treatment contributed to good outcomes, highlighting the importance of immunization.
Area of Science:
- Pediatric Oncology
- Infectious Diseases
- Epidemiology
Background:
- Assessing clinical and epidemiological characteristics of pandemic influenza A/H1N1 in immunocompromised children with cancer.
- Focus on children with solid tumors and hematological malignancies.
Purpose of the Study:
- To determine the clinical and epidemiological features of pandemic influenza A/H1N1.
- Evaluate outcomes in immunocompromised pediatric oncology patients.
Main Methods:
- Prospective study during the H1N1 pandemic (August 2009-February 2010).
- Included children with suspected H1N1 infection in a pediatric hematology-oncology unit.
- Laboratory diagnosis via polymerase chain reaction (PCR) on nasopharyngeal wash specimens.
Main Results:
- Identified 57 suspected H1N1 episodes in 40 children; 13% tested positive.
- No significant demographic or clinical differences between H1N1-positive and negative children.
- PCR-positive children had higher ICU admission and mechanical ventilation rates (P=0.03); one H1N1-positive patient died.
Conclusions:
- Febrile immunocompromised pediatric oncology patients with or without influenza A/H1N1 presented similarly with good outcomes.
- Early antiviral treatment and potentially lower virus virulence contributed to favorable results.
- Encouraging influenza immunization in this vulnerable population is recommended.
Background:
Our aim was to determine the clinical and epidemiological features of pandemic influenza A/H1N1 in immunocompromised children with solid tumors and hematological malignancies.
Patients And Methods:
A prospective study was conducted during the H1N1 pandemic between August 2009 and February 2010 in a pediatric hematology-oncology unit. Demographic and clinical data were obtained from all children with suspected H1N1 infection (high fever with or without respiratory symptoms). Laboratory diagnosis of influenza A/H1N1 was performed by means of polymerase chain reaction analysis of nasopharyngeal wash specimens.
Results:
We identified 57 episodes of suspected influenza A/H1N1 infection in 40 children. In all episodes, children were treated with oseltamivir and antibiotics until influenza A/H1N1 results were received. Of all episodes, 13 (22.8%) tested positive for influenza A/H1N1. Two of the H1N1-positive children (15.4%) had been previously immunized against influenza A/H1N1. No differences between H1N1-positive and H1N1-negative children were noted in terms of demographic features, clinical presentation, laboratory findings, and underlying disease.Three polymerase chain reaction-positive (23.0%) children and 1 H1N1-negative (2.3%) child were admitted to the pediatric intensive care unit and were mechanically ventilated (P=0.03). One (7.7%) H1N1-positive patient died versus none of the H1N1-negative patients (P=0.2). The condition of all other children in both the groups improved rapidly during hospitalization.
Conclusions:
Febrile hospitalized pediatric oncology patients, with and without pandemic influenza A/H1N1, had a similar demographic and clinical presentation with a relatively good outcome. This was probably because of early antiviral treatment and possibly because of the relatively low virulence of the virus. Immunization should be encouraged in these patients.
Related Concept Videos
Influenza
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

